China Medical & HealthCare Group Limited
China Medical & HealthCare Group Limited Fundamental Analysis
China Medical & HealthCare Group Limited (COLRF) shows weak financial fundamentals with a PE ratio of 78.70, profit margin of 0.54%, and ROE of 0.48%. The company generates $2.3B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 27.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze COLRF's fundamental strength across five key dimensions:
Efficiency Score
WeakCOLRF struggles to generate sufficient returns from assets.
Valuation Score
ModerateCOLRF shows balanced valuation metrics.
Growth Score
WeakCOLRF faces weak or negative growth trends.
Financial Health Score
ExcellentCOLRF maintains a strong and stable balance sheet.
Profitability Score
WeakCOLRF struggles to sustain strong margins.
Key Financial Metrics
Is COLRF Expensive or Cheap?
P/E Ratio
COLRF trades at 78.70 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, COLRF's PEG of -0.14 indicates potential undervaluation.
Price to Book
The market values China Medical & HealthCare Group Limited at 0.37 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 9.75 times EBITDA. This is generally considered low.
How Well Does COLRF Make Money?
Net Profit Margin
For every $100 in sales, China Medical & HealthCare Group Limited keeps $0.54 as profit after all expenses.
Operating Margin
Core operations generate 3.75 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $0.48 in profit for every $100 of shareholder equity.
ROA
China Medical & HealthCare Group Limited generates $0.25 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
China Medical & HealthCare Group Limited generates limited operating cash flow of $-6.02M, signaling weaker underlying cash strength.
Free Cash Flow
China Medical & HealthCare Group Limited generates weak or negative free cash flow of $-16.04M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.01 in free cash annually.
FCF Yield
COLRF converts -1.17% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
78.70
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.14
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.37
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.61
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.48
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.22
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.005
vs 25 benchmark
ROA
Return on assets percentage
0.003
vs 25 benchmark
ROCE
Return on capital employed
0.02
vs 25 benchmark
How COLRF Stacks Against Its Sector Peers
| Metric | COLRF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 78.70 | 27.91 | Worse (Expensive) |
| ROE | 0.48% | 687.00% | Weak |
| Net Margin | 0.54% | -45285.00% (disorted) | Weak |
| Debt/Equity | 0.48 | 0.33 | Weak (High Leverage) |
| Current Ratio | 1.22 | 2795.76 | Neutral |
| ROA | 0.25% | -13557.00% (disorted) | Weak |
COLRF outperforms its industry in 0 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews China Medical & HealthCare Group Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation